Merck’s 2015 Expected to Be Low Point as Revenue Declines
This article is for subscribers only.
Sales of Merck & Co.’s drugs slumped in the fourth quarter and the company said it will be hurt this year by foreign exchange rates, as the drugmaker issued 2015 adjusted earnings and sales guidance below analysts’ estimates.
Adjusted earnings for 2015 will be $3.32 to $3.47 per share, below the $3.49 per-share average of 19 estimates compiled by Bloomberg. Revenue will be $38.3 billion to $39.8 billion, Merck said in a statement, below the average $40.7 billion estimate.